Nutanix Inc (NTNX) Named Top 2018 Pick At Oppenheimer

Nutanix gets another vote of confidence from Oppenheimer’s Ittai Kidron.

GoPro Inc (GPRO) Execution Is Not the Issue: Oppenheimer

Analyst has become more positive on GoPro’s new, impressive software; cautious only on sustainability.

Is New Teva Pharmaceutical Industries Ltd (ADR) (TEVA) CEO Walking into a Landmine? Oppenheimer and Maxim Weigh In

Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.

Oppenheimer Sees Himax Technologies, Inc. (ADR) (HIMX) as an Overvalued Stock with Lost Growth Potential

Analyst warns that investors betting on Himax are naïve to bearish risks circling overhead.

DJI’s Spark Short Circuits Ambarella Inc (AMBA) Drone Revenue Leading to Weaker Outlook

Ambarella’s computer vision chips present enticing long-term possibilities, says Oppenheimer.

Palo Alto Networks Inc (PANW) New Product Development a Key to Continued Growth: Oppenheimer

Sales reorganization initiatives and improved execution levels are encouraging, says analyst.

Nutanix Inc (NTNX) Sharpens HCI Leadership Position Even as Competition Grows: Oppenheimer

Nutanix posts record high 45% rise in software sales.

Box Inc (BOX) Impresses Oppenheimer Following FQ2 Results Despite Backtrack to Negative Free Cash Flow

Analyst Expects More Upside Later in Fiscal 2018 and Fiscal 2019

Oppenheimer Comments on The Medicines Company (MDCO) Following FDA Approval for VABOMERE

The Medicines Company’s Vabomere – A Solid Option for CarbapenemResistant cUTIs: Oppenheimer

The Medicines Company (MDCO): Inclisiran Shows Momentum on Longer-Term Data, Oppenheimer Weighs in

Yesterday, at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, The Medicines Company (NASDAQ:MDCO) unveiled positive one-year data from the 501-patient …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts